porcin
reproduct
respiratori
syndrom
prr
origin
design
mysteri
swine
diseas
first
recogn
unit
state
late
character
late
abort
stillbirth
weak
piglet
mummi
associ
porcin
respiratori
diseas
complex
arteriviru
identifi
etiolog
agent
scientif
call
porcin
reproduct
respiratori
syndrom
viru
prrsv
two
decad
viru
pathogenesi
studi
indepth
brought
mani
new
insight
two
main
genotyp
european
genotyp
genotyp
north
american
genotyp
genotyp
three
potenti
four
subtyp
alreadi
distinguish
within
european
prrsv
genotyp
subtyp
present
eu
wherea
russian
area
three
four
subtyp
circul
infect
subtyp
limit
clinic
sign
respiratori
disord
observ
grow
pig
contrast
subtyp
virul
infect
subtyp
strain
lena
result
rapid
onset
diseas
high
fever
sever
dyspnea
tachypnea
periorbit
oedema
depress
mortal
prevent
prr
sever
liveattenu
inactiv
vaccin
prrsv
commerci
avail
attenu
vaccin
significantli
shorten
virem
phase
post
challeng
concern
revers
virul
low
level
protect
upon
challeng
heterolog
prrsv
strain
commerci
inactiv
vaccin
safe
provid
suffici
level
protect
despit
sever
attempt
vaccin
provid
full
protect
current
circul
prrsv
strain
might
explain
low
antigen
degre
similar
vaccin
challeng
strain
immun
evas
charact
viru
coexist
differ
subtyp
europ
emphas
need
crossprotect
vaccin
recent
inform
avail
concern
efficaci
prrsv
subtyp
vaccin
prrsv
subtyp
strain
lena
surprisingli
commerci
avail
attenu
subtyp
vaccin
base
dv
strain
offer
partial
protect
upon
east
european
strain
posit
result
led
present
studi
clinic
virolog
protect
anoth
commerci
avail
attenu
subtyp
vaccin
base
spanish
prrsv
isol
evalu
upon
infect
virul
subtyp
prrsv
strain
lena
vaccin
advers
local
system
effect
observ
upon
vaccin
challeng
effect
vaccin
bodi
temperatur
upon
challeng
present
fig
overal
slight
benefici
effect
vaccin
observ
brief
mean
bodi
temperatur
control
pig
higher
compar
vaccin
anim
day
post
challeng
dpc
although
differ
statist
signific
also
area
curv
auc
valu
fever
threshold
higher
nonvaccin
group
vaccin
group
signific
benefici
effect
observ
number
fever
day
ie
total
number
day
anim
show
fever
throughout
observ
period
day
control
anim
versu
day
vaccin
anim
also
number
anim
show
fever
per
day
throughout
observ
period
significantli
lower
vaccin
group
mild
respiratori
disord
observ
dpc
nonvaccin
anim
dpc
vaccin
anim
anim
except
one
unvaccin
pig
show
respiratori
sign
least
one
time
point
observ
period
respiratori
disord
last
till
week
post
challeng
score
rang
nonvaccin
anim
vaccin
anim
signific
differ
observ
mean
respiratori
score
group
throughout
studi
auc
valu
significantli
higher
nonvaccin
group
vaccin
anim
signific
benefici
effect
observ
number
anim
show
respiratori
sign
per
day
throughout
observ
period
slight
reduct
liveli
observ
dpc
nonvaccin
anim
dpc
vaccin
anim
last
till
week
post
challeng
anim
show
reduc
activ
least
two
time
point
observ
period
reduct
liveli
associ
occurr
fever
discolor
ear
regularli
observ
control
anim
dpc
till
end
experi
vaccin
group
mild
discolor
ear
observ
anim
dpc
clinic
disord
eye
conjunct
seen
dpc
unvaccin
anim
dpc
vaccin
anim
nonvaccin
anim
show
mild
conjunct
least
two
time
point
observ
period
three
five
vaccin
anim
show
mild
conjunct
least
one
time
point
observ
period
auc
valu
significantli
higher
nonvaccin
group
vaccin
anim
signific
benefici
effect
also
observ
number
day
conjunct
observ
day
control
anim
versu
day
vaccin
anim
gener
pig
show
similar
growth
rate
independ
vaccin
mean
bodi
weight
nonvaccin
group
arriv
challeng
euthanasia
kg
kg
kg
respect
time
point
bodi
weight
anim
vaccin
group
kg
kg
kg
respect
necropsi
dpc
macroscop
lung
lesion
found
control
pig
vaccin
pig
total
affect
lung
area
pig
vari
control
group
vaccin
group
mean
total
affect
lung
area
significantli
differ
group
time
arriv
dpc
pig
serolog
virolog
neg
prrsv
determin
immunoperoxidas
monolay
assay
ipma
viru
titrat
figur
repres
evolut
ipma
antibodi
titer
cours
experi
vaccin
unvaccin
control
pig
control
pig
remain
seroneg
challeng
vaccin
pig
seroconvert
within
two
week
vaccin
titer
dpc
challeng
increas
ipma
antibodi
titer
observ
anim
within
two
week
figur
repres
evolut
viru
neutral
vn
antibodi
titer
prrsv
vaccin
control
group
vn
antibodi
prrsv
lv
detect
challeng
challeng
vn
antibodi
prrsv
lena
detect
one
five
vaccin
anim
low
titer
dpc
similar
pattern
elisa
antibodi
observ
ipma
antibodi
signific
differ
found
viral
shed
nasal
secret
viral
shed
observ
dpc
group
fig
titer
peak
dpc
control
group
dpc
vaccin
group
peak
mean
titer
tissu
cultur
infecti
dose
end
point
mg
mg
respect
control
group
viru
shed
observ
least
dpc
end
experi
one
six
pig
still
shed
viru
mg
five
vaccin
pig
viral
shed
observ
anim
till
dpc
two
anim
shed
viru
till
dpc
signific
differ
viru
titer
found
dpc
moreov
auc
valu
viru
secret
significantli
lower
vaccin
pig
nonvaccin
pig
result
viru
titrat
sera
viremia
shown
fig
viru
present
sera
anim
dpc
peak
observ
dpc
control
group
dpc
vaccin
group
control
group
viremia
last
least
dpc
end
experi
two
six
piglet
still
virem
although
low
titer
vaccin
group
viremia
last
dpc
despit
shorter
durat
viremia
signific
differ
observ
mean
viru
titer
control
vaccin
pig
also
signific
differ
seen
auc
valu
group
control
anim
versu
vaccin
anim
reproduct
failur
earli
farrow
late
abort
still
weakborn
piglet
sow
infertil
boar
one
hand
respiratori
disord
piglet
hand
hallmark
prr
depend
strain
genotyp
host
genotyp
coinfect
diverg
clinic
sign
observ
piglet
pig
well
protect
challeng
reinfect
homolog
strain
natur
infect
mimick
use
modifiedl
vaccin
howev
heterolog
challeng
differ
level
protect
obtain
gener
anim
partial
protect
clinic
virolog
labarqu
et
al
found
evid
genet
divers
within
european
strain
subtyp
affect
efficaci
european
vaccin
similar
find
describ
natur
exposur
within
subtyp
present
studi
efficaci
vaccin
prr
genotyp
subtyp
examin
upon
challeng
prrsv
strain
lena
genotyp
subtyp
mean
durat
fever
shorten
number
fever
day
significantli
reduc
vaccin
pig
compar
unvaccin
control
pig
score
respiratori
eye
disord
assign
fewer
vaccin
anim
control
pig
base
result
vaccin
consid
rais
immun
give
partial
clinic
protect
heterolog
infect
addit
vaccin
prr
offer
also
partial
virolog
protect
signific
differ
mean
nasal
prrsv
titer
observ
dpc
titer
reduc
mg
respect
addit
total
nasal
viral
shed
auc
upon
challeng
significantli
lower
factor
similar
find
concern
nasal
secret
vaccin
commerci
avail
liveattenu
vaccin
base
dv
strain
upon
challeng
prrsv
lena
recent
describ
high
titer
nasal
secret
control
anim
might
influenc
process
viral
shed
sinc
transmiss
viral
shed
consid
effici
way
reinfect
pen
mate
measur
safeti
efficaci
commerci
avail
vaccin
present
studi
sudden
drop
prrsvtiter
nasal
secret
observ
dpc
control
anim
three
control
pig
secret
viru
dpc
vaccin
group
one
piglet
shed
prrsv
dpc
ratio
reinfect
control
pig
reinfect
vaccin
piglet
suggest
protect
effect
vaccin
agreement
previou
studi
although
experiment
design
allow
us
determin
transmiss
ratio
despit
posit
outcom
nasal
shed
vaccin
prr
slightli
reduc
durat
viremia
studi
tru
et
al
viremia
significantli
reduc
upon
challeng
prrsv
strain
lena
pig
vaccin
commerci
avail
liveattenu
vaccin
base
dv
strain
differ
protect
might
explain
differ
factor
age
breed
pig
interv
vaccin
challeng
vaccin
challeng
viru
titer
antigen
homolog
vaccin
strain
challeng
strain
although
region
respons
induct
neutral
antibodi
cellular
immun
identifi
clear
correl
genet
homolog
antigen
homolog
therefor
difficult
estim
impact
slight
genet
differ
immunogen
vaccin
viru
protect
upon
challeng
prrsv
strain
dv
lena
ident
wherea
bi
lena
ident
differ
outcom
studi
relat
genet
background
opinion
piglet
came
farm
major
differ
studi
vaccinationchalleng
interv
studi
describ
tru
et
al
interv
week
two
four
week
longer
present
experi
infect
vaccin
prrsv
immun
slowli
induc
shown
protect
six
eight
week
vaccin
better
four
week
viru
neutral
vn
antibodi
crucial
role
prevent
diseas
caus
equin
arter
viru
eav
hors
lactat
dehydrogenaseelev
viru
ldv
mice
similarli
inhibit
prrsv
replic
achiev
vn
antibodi
howev
neutral
antibodi
appear
late
prrsv
infect
vaccin
modifiedl
prrsv
vaccin
thu
surprisingli
present
studi
vn
antibodi
detect
fourweek
vaccinationchalleng
interv
homolog
challeng
vn
antibodi
challeng
viru
boost
contrast
genotyp
heterolog
challeng
vn
antibodi
challeng
viru
detect
challeng
subtyp
strain
lena
vn
antibodi
lena
detect
one
prrsvaccin
anim
week
similar
experi
use
anoth
prrsv
subtyp
vaccin
base
dv
strain
pig
develop
vn
antibodi
lena
week
prrsv
lena
challeng
latter
studi
viremia
clearli
reduc
compar
nonvaccin
control
group
might
explain
part
presenc
neutral
antibodi
howev
present
studi
pig
develop
vn
antibodi
lena
show
shorter
durat
viremia
nasal
shed
role
vn
antibodi
protect
therefor
disput
certain
branch
cellmedi
immun
like
import
assess
measur
interferon
gamma
produc
cell
studi
test
determin
level
avail
laboratori
therefor
assess
agre
result
could
given
extra
valu
implement
techniqu
current
studi
present
studi
demonstr
vaccin
modifiedl
vaccin
prr
provid
partial
clinic
virolog
protect
upon
challeng
prrsv
lena
partial
clinic
virolog
protect
obtain
current
commerci
avail
subtyp
prrsv
vaccin
need
design
vaccin
give
better
protect
prrsv
lena
eleven
piglet
purchas
prrsvneg
farm
immedi
wean
neg
prrsv
statu
confirm
serolog
ipma
viru
titrat
sera
nasal
secret
collect
upon
arriv
acclimat
seven
day
anim
randomli
assign
two
group
one
group
n
vaccin
intramuscularli
ml
commerci
avail
live
attenu
prrsv
subtyp
vaccin
prr
laboratorio
hipra
sa
retitr
reveal
titer
per
ml
second
group
mockvaccin
phosphat
buffer
salin
pb
n
week
post
vaccin
pig
intranas
inocul
ml
prr
viru
strain
lena
subtyp
blood
collect
weekli
base
monitor
serolog
statu
ipma
vn
follow
cours
viremia
nasal
shed
upon
challeng
blood
nasal
swab
collect
dpc
week
post
challeng
experi
termin
intraven
inject
overdos
sodium
pentobarbit
natrium
pentobarbit
kela
laboratoria
nv
hoogstraten
belgium
fix
prrsv
lelystad
viru
lv
respect
lena
infect
cell
microtit
plate
use
ipma
serial
twofold
dilut
serum
sampl
ad
plate
incub
hour
wash
secondari
goat
antiswin
igg
label
peroxidas
ad
anoth
hour
plate
wash
substrat
solut
aec
ad
well
follow
incub
plate
room
temperatur
minut
ipma
titer
reciproc
highest
dilut
give
color
infect
cell
vn
antibodi
detect
sn
assay
cell
use
prrsv
lv
sera
collect
challeng
prrsv
lena
sera
collect
challeng
twofold
dilut
serum
sampl
prepar
appropri
prrsv
strain
titer
ad
mix
plate
incub
hour
mixtur
subsequ
transfer
confluent
monolay
cell
microtit
plate
cell
screen
day
inocul
neutral
titer
sera
record
reciproc
highest
dilut
inhibit
cpe
inocul
well
addit
sampl
posit
ratio
determin
use
civtest
sui
prr
elisa
laboratorio
hipra
sa
aim
detect
antibodi
european
prrsv
isol
elisa
perform
accord
manufactur
instruct
bodi
weight
monitor
pig
upon
arriv
dpc
challeng
dpc
euthanasia
dpc
local
side
effect
well
bodi
temperatur
record
day
post
vaccin
dpv
challeng
anim
monitor
daili
presenc
clinic
sign
till
day
post
challeng
particular
attent
prr
relat
clinic
sign
clinic
paramet
includ
bodi
temperatur
respiratori
symptom
liveli
discolor
ear
clinic
symptom
eye
presenc
diarrhea
score
assign
variou
paramet
allow
object
comparison
group
score
base
methodolog
describ
karniychuk
et
al
weesendorp
et
al
lung
collect
macroscop
lung
lesion
given
score
visual
observ
computerassist
analysi
percentag
lung
surfac
affect
pneumonia
estim
multipli
lung
lesion
score
per
lobe
rel
proport
lobe
entir
lung
dpc
serum
test
virolog
titrat
follow
cours
viremia
addit
nasal
secret
collect
dri
swab
copan
ml
transport
medium
phosphat
buffer
salin
supplement
antibiot
fetal
calf
serum
ad
swab
vortex
centrifug
supernat
use
viru
titrat
brief
porcin
alveolar
macrophag
pam
cultiv
hour
inocul
dilut
either
serum
nasal
secret
hour
cell
fix
virusinfect
cell
subsequ
evalu
subsequ
incub
prrsvspecif
monoclon
antibodi
nucleocapsid
protein
studi
conduct
complianc
provis
direct
kb
receiv
approv
number
ec
data
analyz
graphpad
prism
softwar
graphpad
softwar
inc
san
diego
ca
usa
result
shown
repres
mean
standard
deviat
sd
ipma
titer
geometr
mean
valu
sd
serolog
titer
ipma
vn
well
viral
load
logtransform
prior
analysi
gross
patholog
score
area
curv
auc
analyz
use
nonparametr
mann
whitney
test
durat
evalu
ttest
statist
analysi
continu
data
perform
use
repeatedmeasur
twoway
analysi
varianc
ranova
bonferroni
posttest
result
pvalu
consid
statist
signific
